Issue #66

One size does NOT fit all. Plus, Netflix goes Blue Zone

August 31, 2023

August 31, 2023 | Issue #66

Hello... Personalized medicine is coming... Are you ready? 

In this week's newsletter:🏥 One Size Does NOT Fit All 💰 Serina and AgeX Merge🌐 Blue Zones Now on Netflix 

Personalized Medicine: What It Is, Why It’s Popular, and Why It’s Not Going Anywhere

The math just doesn’t add up. Although the US spends more money per capita on healthcare than any other country in the world, the US lags in life expectancy, ranking 48th highest in the world. From a purely return on investment standpoint, the costs certainly outweigh the benefits here…There are a number of reasons why life expectancy falls short in the US.Unfortunately, life expectancy is directly correlated to where in the US someone lives, their demographics, and how much money they make – factors that should have zero bearing on how long someone lives. What life expectancy should correlate with is the healthcare spend –  but it doesn't. Not only does the math not add up, but consumers have begun to feel it themselves, with more than half of US patients feeling like the healthcare system deserves a “C” or below. It’s worth pointing out that doctors aren’t the bad guys. In fact, many of them aren’t thrilled with the way the system is set up and are increasingly burned out themselves.That said, there’s an undeniable shift to new healthcare models that place the focus back on the consumer, a large part of that shift includes the rise of personalized medicine.  Click below to learn about current challenges and the future of personalized medicine...

  • Ayun is looking for a CEO APPLY HERE. 

  • Browse thousands of jobs in the longevity industry, updated daily, in Spannr's new Jobs database HERE. 

  • Serina Therapeutics, Inc. (“Serina”), a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson’s Disease and other neurological diseases, entered into a merger agreement with AgeX Therapeutics, Inc. (NYSE American: AGE) (“AgeX”) on August 29, 2023, under which Serina will merge with a wholly-owned subsidiary of AgeX in an all-stock transaction. Upon completion of the transaction, the combined company will operate under the Serina Therapeutics name, and the combined company’s common stock is expected to trade on the NYSE American under the ticker symbol “SER.”

  • Explore Spannr's Longevity Investor database HERE.

  • Want to live healthier longer? Visual guide shows how longevity science looks to slow diseases of aging (USA Today)

  • Wealthy People Are Getting Full-Body Scans. Early Detection or Unnecessary? (WSJ)

  • Longevity is challenging people to reimagine their later years. One age cohort is ‘carrying the most stress and burden,’ research finds (CNBC)

  • Some cancer screening tests may not extend lifespans, study finds (The Guardian)

  • How We Age—and How Scientists Are Working to Turn Back the Clock (WSJ)

  • Robert Nelsen invested millions to slow down the aging process. Here's his antiaging routine, including a suit that sends electric pulses. (Insider)

  • Maintaining stable weight dramatically increases odds of living 100+ years (Earth)

  • Want to live to 100? "Blue Zones" expert shares longevity lessons in new Netflix series (CBS News)

  • Bloodthirsty Silicon Valley vampires won't stop: It's time to stake our claim (Salon) 

  • The longevity secrets of Singapore, the 6th blue zone city where people are living the longest, happiest lives (Fortune)

Performance:

Latest Price: $103.237d-Return: -0.5%Market Cap: $10.6b

Big Movers:Athersys (ATHX): 20%Clene (CLNN): 15.15%Capricor (CAPR): -12.19%

ABOUT SPANNR

We are dedicated to helping people understand the biggest business and health story of all time: the unprecedented transformation of society that will result from extending human healthspan and lifespan.

If you have any questions about Spannr or want to get to know us better, 

 – we'd love to hear from you. We appreciate your interest in what we are creating.